News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlycoMimetics, Inc. (GLYC) Announces Presentation Of Rivipansel Data In Pediatric Patients At American Society Of Pediatric Hematology Oncology 27th Annual Meeting


5/15/2014 9:55:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that data from a Phase 2 clinical trial of its lead drug candidate rivipansel (GMI-1070) in pediatric patients has been presented at the American Society of Pediatric Hematology Oncology (ASPHO) 27th Annual Meeting. As part of the symposium entitled, “Sickle Cell Disease: Saving the Brain and Treating the Pain,” Timothy McCavit, M.D., M.S., Assistant Professor of Pediatric Hematology-Oncology at UT Southwestern Medical Center, highlighted the results observed in a randomized, multi-center, double-blind, adaptive Phase 2 study of rivipansel in pediatric sickle cell disease patients with vaso-occlusive crisis (VOC). The ASPHO Meeting is taking place May 14 through May 17 at the Palmer House Hilton in Chicago.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES